KYV-101 – Talk Bio

Actionable Insights Powered by AI

Kyverna Therapeutics Cuts 16% of Staff in Q1 2025 Amid Pipeline Focus

Kyverna Therapeutics; layoffs; biotech; staff reduction; Q1 2025; CAR-T; autoimmune diseases; pipeline development; KYV-101